Equities Analysts Offer Predictions for BCRX FY2026 Earnings

Key Points

• Cantor Fitzgerald has raised its FY2026 earnings estimates for BioCryst Pharmaceuticals from $0.27 to $0.45 per share, maintaining an "Overweight" rating with a target price of $20.00.
• BioCryst Pharmaceuticals reported a quarterly earnings per share of $0.15, surpassing analysts' expectations by $0.12 and achieving a revenue increase of 49.5% year-over-year.
• Investment analysts have shown a positive outlook, with nine buy ratings and an average target stock price of $16.70 across various research reports.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities researchers at Cantor Fitzgerald upped their FY2026 earnings estimates for BioCryst Pharmaceuticals in a note issued to investors on Tuesday, August 5th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the biotechnology company will post earnings of $0.45 per share for the year, up from their previous forecast of $0.27. Cantor Fitzgerald currently has a "Overweight" rating and a $20.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to the consensus estimate of $149.59 million. BioCryst Pharmaceuticals's revenue was up 49.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.06) earnings per share.

BCRX has been the subject of several other research reports. Wedbush boosted their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research note on Monday, June 30th. Needham & Company LLC reaffirmed a "buy" rating and issued a $17.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday. Barclays boosted their price objective on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Royal Bank Of Canada reissued an "outperform" rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Finally, HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Stock Down 2.7%

Shares of NASDAQ BCRX opened at $8.37 on Thursday. The business has a 50-day simple moving average of $9.42 and a two-hundred day simple moving average of $8.74. BioCryst Pharmaceuticals has a 52 week low of $6.01 and a 52 week high of $11.31. The company has a market cap of $1.75 billion, a P/E ratio of -46.56, a P/E/G ratio of 1.27 and a beta of 1.10.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Lazard Asset Management LLC increased its position in shares of BioCryst Pharmaceuticals by 68.1% during the fourth quarter. Lazard Asset Management LLC now owns 161,516 shares of the biotechnology company's stock valued at $1,214,000 after acquiring an additional 65,420 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth $80,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter valued at $79,000. Jupiter Asset Management Ltd. lifted its stake in BioCryst Pharmaceuticals by 82.4% during the 1st quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock valued at $16,117,000 after acquiring an additional 971,040 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 3.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company's stock valued at $3,016,000 after acquiring an additional 11,581 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.